Long-acting inhaled bronchodilators for cystic fibrosis

Cystic fibrosis (CF) is the most common life-limiting autosomal recessive inherited disease in white populations; it affects approximately 70,000 children and adults worldwide[1], with a rate of one in 2500 newborns in the UK[2]. It was once considered a childhood disease, but with improvements in diagnosis and treatments, many people with CF are living well into adulthood. In 2016, data from the UK Cystic Fibrosis National Registry reported a median predicted survival of 47 years[3].

Source: Paediatric Respiratory Reviews - April 20, 2018 Category: Respiratory Medicine Authors: Sherie Smith, Christopher T. Edwards Source Type: research